This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Cardiac hypertrophy	Transient receptor potential cation channel, subfamily C, member 3 (TRPC3)	<p>An SAR study characterized a pyrazole compound, Pyr3, as a selective TRPC3 channel inhibitor that could be useful for treating cardiac hypertrophy. In rat neonatal cardiomyocytes, Pyr3 suppressed several angiotensin II (AngII)-induced hypertrophic responses, including actin reorganization, brain natriuretic peptide expression and protein synthesis. In a mouse model of cardiac hypertrophy, Pyr3 suppressed increases in both heart size and expression of atrial natriuretic peptide mRNA, a biomarker of cardiac hypertrophy. Next steps include optimizing the structure of the Pyr compounds for higher selectivity.</p> <p>SciBX 2(12); doi:10.1038/scibx.2009.491 Published online March 26, 2009</p>	Unpatented; unlicensed	<p>Kiyonaka, S. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online March 16, 2009; doi:10.1073/pnas.0808793106</p> <p>Contact: Yasuo Mori, Kyoto University, Kyoto, Japan e-mail: mori@sbchem.kyoto-u.ac.jp</p>